N

Nektar Therapeutics

D
NKTR
USD
-0.015
(-1.0791%)
Market Closed
110,033.00
Volume
-0.97
EPS
-
Div Yield
-1.527778
P/E
253,109,283.63
Market Cap
Today
-1.0791%
1 Week
15.546%
1 Month
7.422%
6 Months
-8.333%
12 Months
150.912%
Year To Date
141.228%
All Time
-91.997%

Title:
Nektar Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people.The group derives revenue from the United States and the Rest of the World.
Do you need help or have a question?